| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STAT6 |
| Uniprot No | P42226 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 627-837aa |
| 氨基酸序列 | MSHYKPEQMGKDGRGYVPATIKMTVERDQPLPTPELQMPTMVPSYDLGMA PDSSMSMQLGPDMVPQVYPPHSHSIPPYQGLSPEESVNVLSAFQEPHLQM PPSLGQMSLPFDQPHPQGLLPCQPQEHAVSSPDPLLCSDVTMVEDSCLSQ PVTAFPQGTWIGEDIFPPLLPPTEQDLTKLLLEGQGESGGGSLGAQPLLQ PSHYGQSGISMSLEHHHHHH |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于STAT6重组蛋白的参考文献及简要摘要：
---
1. **文献名称**：*Structural insights into STAT6 signaling by interleukin-4*
**作者**：Xiao, W., Chen, X., & Li, Z.
**摘要**：通过X射线晶体学解析了STAT6重组蛋白与IL-4受体复合物的三维结构，揭示了STAT6在IL-4信号通路中被激活的分子机制，为靶向STAT6的免疫疾病治疗提供结构基础。
---
2. **文献名称**：*Recombinant STAT6 expression and its role in Th2 cell differentiation*
**作者**：Kubo, M., & Nakayama, T.
**摘要**：研究利用重组STAT6蛋白在体外模型中验证其调控Th2细胞分化的功能，发现STAT6磷酸化水平与IL-4诱导的基因表达直接相关，为过敏性疾病机制研究提供依据。
---
3. **文献名称**：*Optimization of prokaryotic expression and purification of human STAT6*
**作者**：Zhang, Y., et al.
**摘要**：报道了一种高效的大肠杆菌表达系统用于生产可溶性STAT6重组蛋白，通过优化诱导条件和纯化步骤获得高纯度蛋白，适用于体外激酶活性检测及抗体开发。
---
4. **文献名称**：*STAT6-dependent gene regulation in cancer: Insights from recombinant protein assays*
**作者**：Chen, L., & Wang, H.
**摘要**：利用STAT6重组蛋白进行染色质免疫沉淀测序(ChIP-seq)，鉴定了其在乳腺癌细胞中调控的靶基因网络，揭示了STAT6通过表观遗传修饰促进肿瘤转移的新机制。
---
(注：上述文献为模拟示例，实际引用需核实真实存在的论文信息。)
**Background of STAT6 Recombinant Protein**
STAT6 (Signal Transducer and Activator of Transcription 6) is a transcription factor critical for mediating cellular responses to interleukin-4 (IL-4) and interleukin-13 (IL-13), key cytokines involved in immune regulation. It plays a pivotal role in Th2 cell differentiation, B cell antibody class switching (e.g., IgE production), and macrophage polarization. Upon cytokine binding to receptors, STAT6 is phosphorylated, dimerizes via its SH2 domain, and translocates to the nucleus to activate target genes, including those regulating allergic inflammation, immune tolerance, and tissue repair.
Recombinant STAT6 protein is engineered in vitro using expression systems like *E. coli*, insect, or mammalian cells, ensuring high purity and bioactivity. It typically retains functional domains, such as the DNA-binding and SH2 regions, enabling studies on its structure, phosphorylation dynamics, and interactions with DNA or partner proteins. Researchers utilize STAT6 recombinant protein to dissect IL-4/IL-13 signaling pathways, screen for inhibitors or activators in drug discovery, and model diseases like asthma, cancer, or autoimmune disorders.
Its applications extend to *in vitro* assays (e.g., EMSA, ELISA), antibody development, and mechanistic studies of STAT6 dysregulation in pathologies. By providing a controlled, scalable source of functional protein, recombinant STAT6 accelerates both basic research and therapeutic innovation targeting Th2-driven conditions.
×
